– Richard Eisenstadt has been appointed Chief Financial Officer (CFO) of Aytu BioPharma (NASDAQ:AYTU), succeeding David Green, who stepped down on March 31, 2021.
– Mr. Eisenstadt most recently served as CFO at Neos Therapeutics, where he raised over $340 million in private and public equity and debt financings and facilitated the company’s transformation from clinical to commercial operations prior to its March 2021 merger with Aytu.
Aytu Biopharma Inc(AYTU) is a stock of interest due to the large impact the company has on the market. Here at Wall Street Facts we only cover the best stocks so make sure you check out our other articles. Today we will be diving deep into all of the essential information you need to know about AYTU. We will be studying the movement so you can make the best decision as an investor. The stock has moved downwards today by 5.84%. The high for today is 7.55 and today’s low is 7.02. This information is critical in deciding whether this investment is risky or not. We can see the stock is trending downwards, which means the volume of people selling this stock is greater than people buying it.
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
As an investor, you can get an idea of where the stock is trending by the forecast. In this case, the high forecast for Aytu Biopharma Inc is $24.00 and the low forecast is $18.00. We can get a look into the future by looking at past trends. Looking at Aytu Biopharma Inc’s 5-year movement it seems it has fallen 99%. Overall, Aytu Biopharma Inc is in great shape going forward. They have a strong market cap of $128.60M and a very bright future ahead of them.